KR910020007A - 3-[1-티아졸리디닐부틸-4-피페라지닐]-1h-인다졸, 이의 제조방법 및 이의 약제로서의 용도 - Google Patents

3-[1-티아졸리디닐부틸-4-피페라지닐]-1h-인다졸, 이의 제조방법 및 이의 약제로서의 용도 Download PDF

Info

Publication number
KR910020007A
KR910020007A KR1019910008144A KR910008144A KR910020007A KR 910020007 A KR910020007 A KR 910020007A KR 1019910008144 A KR1019910008144 A KR 1019910008144A KR 910008144 A KR910008144 A KR 910008144A KR 910020007 A KR910020007 A KR 910020007A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
lower alkyl
piperazinyl
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019910008144A
Other languages
English (en)
Other versions
KR100215616B1 (ko
Inventor
제이. 리브 니콜라스
티. 스트러프체프스키 죠셉
지. 저캑 존
보듀 케니쓰
Original Assignee
원본미기재
훽스트-러셀 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 훽스트-러셀 파마슈티칼즈 인코포레이티드 filed Critical 원본미기재
Publication of KR910020007A publication Critical patent/KR910020007A/ko
Application granted granted Critical
Publication of KR100215616B1 publication Critical patent/KR100215616B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음

Description

3-[1-티아졸리디닐부틸-4-피페라지닐]-1H-인다졸, 이의 제조방법 및 이의 약제로서의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 하기 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 산 부가염, 및 이의 광학적, 기하학적 및 입체이성체, 및 이의 라세미 혼합물.
  3. 상기식에서, R1및 R2는 각각 수소 또는 저급 알킬이거나, 또는 이들이 결합된 탄소원자와 함께 사이클로펜탄, 사이클로헥산 또는 사이클로헵탄 환을 형성하고, R3및 R4는 각각 수소 또는 저급 알킬이거나, 또는 이들이 결합된 탄소원자와 함께 사이클로펜탄, 사이클로헥산 또는 사이클로헵탄 환을 형성하며, R5는 수소, 저급알킬, 알카노일 또는 아로일이고, X는 할로겐, 저급알킬 또는 알콕시이며, m은 0내지 3의 정수이다.
  4. 제1항에 있어서, R3, R4, R5가 각각 수소 또는 저급 알킬이고, X가 할로겐이며, m이 0 또는 1인 화합물.
  5. 제2항에 있어서, R3및 R4가 각각 수소 또는 메틸이고, R5가 수소이며, X가 불소이고, m이 0 또는 1인 화합물.
  6. 제3항에 있어서, R1및 R2가 각각 수소 또는 메틸이거나, 또는 이들이 결합된 탄소원자와 함께 사이클로펜탄 또는 사이클로헥산환을 형성하는 화합물.
  7. 제1항에 있어서,3-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-1-티아-3-아자스피로[4,5]데칸-4-온인 화합물.
  8. 제1항에 있어서, 3-(4-[1-(6-플루오로-1H-인다졸-3-일]-4-피페라지닐]부틸)-5-메틸-4-티아졸리디논인 화합물.
  9. 제1항에 있어서, 3-(4-[1-(6-플루오로-1H-인다졸-3-일)-4-피페라지닐]부틸)-1-타아-3-아자스피로[4,5]데칸-4-온인 화합물.
  10. 제1항에 있어서, 3-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-1-티아-3-아자스피로[4,5]노난-4-온인 화합물.
  11. 제1항에 있어서, 3-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-5,5-디메틸-4-티아졸리디논인 화합물.
  12. 활성성분으로서의 제1항의 화합물 및 약제학적으로 허용되는 이의 담체를 포함하는 약제학적 조성물.
  13. 정신병 치료 활성을 갖는 약제를 제조하기 위한 제1항의 화합물의 용도.
  14. a)하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시켜, R5가 수소인 제1항의 일반식(Ⅰ)의 화합물을 수득하고, 임의로 b)R5가 수소인 제1항의 일반식(Ⅰ)의 화합물을 적합한 알킬화제와 반응시켜, R5가 저급 알킬인 제1항의 일반식(Ⅰ)의 화합물을 수득함을 특징으로 하여, 제1항의 화합물을 제조하는 방법.
  17. 상기식에서, R1, R2, R3, R4, X 및 m은 제1항에서 정의한 바와 같고, R5는 수소 또는 저급알킬이나, 단 일반식(Ⅲ)에서 R5는 수소이다.
  18. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910008144A 1990-05-21 1991-05-20 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물 Expired - Fee Related KR100215616B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/526,089 US5041445A (en) 1990-05-21 1990-05-21 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles
US526,089 1990-05-21

Publications (2)

Publication Number Publication Date
KR910020007A true KR910020007A (ko) 1991-12-19
KR100215616B1 KR100215616B1 (ko) 1999-08-16

Family

ID=24095872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008144A Expired - Fee Related KR100215616B1 (ko) 1990-05-21 1991-05-20 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물

Country Status (23)

Country Link
US (1) US5041445A (ko)
EP (1) EP0458234B1 (ko)
JP (1) JP3161755B2 (ko)
KR (1) KR100215616B1 (ko)
AT (1) ATE178327T1 (ko)
AU (1) AU642243B2 (ko)
CA (1) CA2042982A1 (ko)
CZ (1) CZ280005B6 (ko)
DE (1) DE69131057T2 (ko)
DK (1) DK0458234T3 (ko)
ES (1) ES2130125T3 (ko)
FI (1) FI94757C (ko)
GR (1) GR3030233T3 (ko)
HU (1) HU215845B (ko)
IE (1) IE911708A1 (ko)
IL (1) IL98184A (ko)
MX (1) MX25858A (ko)
NO (1) NO179749C (ko)
NZ (1) NZ238184A (ko)
PL (1) PL165731B1 (ko)
PT (1) PT97720B (ko)
RU (2) RU2038355C1 (ko)
ZA (1) ZA913794B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801186A (en) 1987-11-20 1998-09-01 Hoechst Marion Roussel, Inc. 3- 4-(1-substituted-4-piperazinyl)butyl!-4-thiazolidinone and related compounds
ATE81123T1 (de) * 1987-11-20 1992-10-15 Hoechst Roussel Pharma 3-(4(1-substituierte-4-piperazinyl)butyl>-4thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
CA2157348A1 (en) * 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
EP1984351A1 (en) * 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
CN101801194A (zh) * 2007-08-15 2010-08-11 记忆医药公司 具有5-ht6受体亲和力的3’取代的化合物
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
JP5760300B2 (ja) 2009-09-10 2015-08-05 株式会社リコー インクジェット用インク組成物材料及びインクジェット用インク組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100282A (en) * 1972-12-23 1978-07-11 Boehringer Ingelheim Gmbh N-Aryl-N'-(phenyl- or phenoxy-alkyl)-piperazines and salts thereof
DE3132916A1 (de) * 1981-08-20 1983-03-03 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenylindazol-3-on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4732984A (en) * 1985-10-17 1988-03-22 American Home Products Corporation Piperazinoisothiazolones with psychotropic activity
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
ATE81123T1 (de) * 1987-11-20 1992-10-15 Hoechst Roussel Pharma 3-(4(1-substituierte-4-piperazinyl)butyl>-4thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles

Also Published As

Publication number Publication date
MX25858A (es) 1993-09-01
NO911921L (no) 1991-11-22
RU2038355C1 (ru) 1995-06-27
US5041445A (en) 1991-08-20
DE69131057D1 (de) 1999-05-06
HU911697D0 (en) 1991-11-28
FI94757C (fi) 1995-10-25
PT97720B (pt) 1998-09-30
IL98184A (en) 1995-03-15
PL290327A1 (en) 1992-05-04
JPH04226979A (ja) 1992-08-17
ES2130125T3 (es) 1999-07-01
NO179749C (no) 1996-12-11
EP0458234B1 (en) 1999-03-31
FI94757B (fi) 1995-07-14
AU7618191A (en) 1991-11-21
RU2105765C1 (ru) 1998-02-27
DE69131057T2 (de) 1999-09-09
ZA913794B (en) 1992-02-26
IE911708A1 (en) 1991-12-04
NO911921D0 (no) 1991-05-16
HUT61018A (en) 1992-11-30
EP0458234A3 (en) 1992-09-30
HU215845B (hu) 1999-04-28
IL98184A0 (en) 1992-06-21
PL165731B1 (pl) 1995-02-28
GR3030233T3 (en) 1999-08-31
NZ238184A (en) 1993-01-27
CZ280005B6 (cs) 1995-09-13
DK0458234T3 (da) 1999-10-11
AU642243B2 (en) 1993-10-14
FI912401L (fi) 1991-11-22
PT97720A (pt) 1992-02-28
EP0458234A2 (en) 1991-11-27
CZ148091A3 (en) 1993-08-11
ATE178327T1 (de) 1999-04-15
JP3161755B2 (ja) 2001-04-25
CA2042982A1 (en) 1991-11-22
FI912401A0 (fi) 1991-05-17
NO179749B (no) 1996-09-02
KR100215616B1 (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
KR910006279A (ko) 3-(1-치환된-4-피페라지닐)-1h-인다졸, 이의 제조방법 및 이의 약제로서의 용도
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
NO163566C (no) 1,5-benzothiazepinderivater som er anvendelige som utgangsmaterialer ved fremstilling av nye, terapeutisk aktive 8-klor-1,5-benzothiazepinderivater.
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
KR910020007A (ko) 3-[1-티아졸리디닐부틸-4-피페라지닐]-1h-인다졸, 이의 제조방법 및 이의 약제로서의 용도
KR890003730A (ko) 1-페닐-3-(1-피페라지닐)-1h-인다졸, 그의 제조방법 및 중간생성물, 및 약제로서의 용도
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
KR860008973A (ko) 2-피롤리돈 유도체
KR880006205A (ko) 치환된 1h-이미다졸
KR880006203A (ko) 융합된 헤테로사이클릭 테트라하이드로아미노 퀴놀리놀 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
NO160445C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
SE7703000L (sv) Forfarande for framstellning av karbostyrilderivat
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
KR960702456A (ko) 4-(p-플로오로페닐)-3-[(3,4-(메틸렌디옥시)페녹시)메틸]피페리딘의 n-p-할로벤조일메틸 유도체(n-p-halobenzoylmethyl derivatives of 4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]piperidine)
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
KR890002079A (ko) 1-[2-(페닐메틸)페닐]피페라진 및 그의 제조방법
KR950014088A (ko) 1,3,4-옥사디아졸-2(3h)-온 유도체, 이것의 제조방법 및 치료에의 이용
SE7909367L (sv) Sett att framstella piperidyl-indol-derivat, ny framstelld forening och dess salter samt anvendning derav sasom lekemedel och farmaceutiska kompositioner innehallande dessa foreningar
NO173276C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive 1,4-disubstituerte-piperidinylderivater
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
ATE7498T1 (de) Cycloheptindolderivate und ihre saeureadditionssalze, ihre herstellung, ihre verwendung als arzneimittel und sie enthaltende zusammensetzungen.
FI871253A0 (fi) 1-/3-(2-dialkylaminoetoxi)-2 -tienyl/-3-fenyl-1-propanoner och deras syraadditionssalter, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska sammansaettningar.

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20020517

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030526

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030526